Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10006032 Predictive biomarker for cancer therapy

Patent 10006032 was granted and assigned to Mologen AG on June, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Manuel Schmidt0

Burghardt Wittig0

Kerstin Kapp0

Matthias Schroff0

Date of Patent

June 26, 2018

0

Patent Application Number

148918690

Date Filed

May 15, 2014

0

Patent Citations Received

US Patent 11578331 Combination comprising immunostimulatory oligonucleotides

US Patent 11957788 Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications

0

US Patent 11364304 Crosslinked micellar spherical nucleic acids

US Patent 11583581 Methods of treating a retroviral infection

Patent Primary Examiner

0

Patent abstract

The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10006032 Predictive biomarker for cancer therapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool